Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 234   

Articles published

JNJ 138.34 +0.41 (0.30%)
price chart
Johnson & Johnson: Dividend King With Good Total Return And Dividend Growth
Johnson & Johnson total return over-performed the DOW average for my 58.0 month test period by 33.72%, which is great. Johnson & Johnson Has increased its dividend for 55 years in a row (a dividend king) and presently has a yield of 2.4% which is above ...
Johnson & Johnson (JNJ) Closes 0.3% Up on the Day for November 21
Latest figures makes these Stock Even More Attractive: Johnson & Johnson ...  StockNewsJournal
The case for Johnson & Johnson
The most important growth engine for Johnson & Johnson is its largest business: the pharmaceutical segment. Several products are largely responsible for driving that growth, especially Imbruvica (for which J&J receives a smaller percentage of sales ...
The Right Time To Buy Johnson & Johnson
No investor wants to feel like they are over paying for a stock, yet mega cap dividend aristocrats like Johnson & Johnson (JNJ), Procter &Gamble (PG) and AbbVie Inc. (ABBV) are widely sought after. These stocks are attractive because of their dividend ...
Analyst's Predictions on Johnson & Johnson (JNJ), Arconic Inc. (ARNC)  StockNewsJournal
Johnson & Johnson (JNJ) Shares Bought by Stonebridge Capital Management Inc.  The Ledger Gazette
Johnson & Johnson beauty challenge crowdsources new skincare tech
Calling all digital entrepreneurs: Johnson & Johnson is looking for creative tech skincare solutions in its Digital Beauty QuickFire Challenge.
Johnson & Johnson Innovation Announces Winner of its Advancing the Safe ...  Markets Insider
Johnson & Johnson wins California lawsuit claiming asbestos in talc caused cancer
(Reuters) - A California jury on Thursday ruled in favor of Johnson & Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company's talc-based products including J&J's Baby Powder.
Johnson & Johnson WINS cancer lawsuit in California - minutes before ...  Daily Mail
Dallas jury orders Johnson & Johnson to pay $247 million to hip implant patients
Johnson & Johnson was ordered Thursday by a Dallas jury to pay $247 million to half a dozen patients who claimed the company hid defects in its Pinnacle artificial hips, its third big-dollar loss over the products.
Johnson & Johnson hit with $247 million verdict in hip implant trial  Reuters
Johnson & Johnson CEO reveals the leadership lessons he learned at West Point
Johnson & Johnson Chairman and CEO Alex Gorsky says being a successful leader all comes down to the valuable lessons he learned as a cadet at the U.S.
Johnson & Johnson drug succeeds in newly diagnosed multiple myeloma patients ...
(Reuters) - Johnson & Johnson's blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with standard therapy alone in patients not previously treated ...
Johnson & Johnson: Janssen Submits Application to US FDA to Expand ...  The Wall Street Transcript
Johnson & Johnson Pipeline Impresses
Johnson & Johnson (JNJ) is a $376 billion market cap company trading at $140 per share focused on innovative health care products for people around the world for over 130 years.
Johnson & Johnson fined $247M in hip implant case
A jury has ordered Johnson & Johnson to pay $247 million to six patients who received Pinnacle hip implants. The fine stems from claims the metal-on-metal hip implants caused tissue death and bone erosion as a result of flaws in their design.
Johnson & Johnson Will Pay Millions for Metal on Metal Hip Implants  Legal Examiner